TrovaGene Inc (NASDAQ:TROV)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.57 and traded as high as $1.15. TrovaGene shares last traded at $1.15, with a volume of 500 shares traded.
Several research analysts recently commented on the company. ValuEngine upgraded TrovaGene from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Maxim Group reiterated a “buy” rating and issued a $6.00 price target on shares of TrovaGene in a research note on Thursday, October 3rd. Finally, Noble Financial reiterated a “buy” rating and issued a $23.00 price target on shares of TrovaGene in a research note on Wednesday, October 2nd.
The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $1.78 and a 200 day moving average of $2.57. The firm has a market cap of $7.15 million, a price-to-earnings ratio of -0.14 and a beta of 0.24.
TrovaGene (NASDAQ:TROV) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.27). TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The business had revenue of $0.14 million during the quarter. As a group, equities research analysts expect that TrovaGene Inc will post -4.02 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Morgan Stanley raised its stake in TrovaGene by 26,190.3% during the second quarter. Morgan Stanley now owns 27,079 shares of the medical research company’s stock valued at $68,000 after buying an additional 26,976 shares in the last quarter. Vanguard Group Inc. raised its stake in TrovaGene by 320.8% during the second quarter. Vanguard Group Inc. now owns 285,150 shares of the medical research company’s stock valued at $713,000 after buying an additional 217,386 shares in the last quarter. Renaissance Technologies LLC raised its stake in TrovaGene by 55.5% during the second quarter. Renaissance Technologies LLC now owns 249,121 shares of the medical research company’s stock valued at $623,000 after buying an additional 88,900 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in TrovaGene during the second quarter valued at approximately $25,000. Hedge funds and other institutional investors own 10.85% of the company’s stock.
About TrovaGene (NASDAQ:TROV)
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Read More: What is a Market Correction?
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.